Initial findings from Biotech's nasal vaccine show 'promising results': Govt | Latest News India - Hindustan Times
close_game
close_game

Initial findings from Biotech's nasal vaccine show 'promising results': Govt

By, Hindustan Times, New Delhi
Sep 09, 2021 08:55 PM IST

After developing India’s first indigenous anti-Covid shot, Covaxin, the Hyderabad-based pharmaceutical company is now developing an intranasal jab for the country.

The findings of the phase one trial of Bharat Biotech International Limited’s nasal vaccine against the coronavirus disease (Covid-19) have been promising, the Centre informed on Thursday, adding that it will prevent virus entry into the body. "Rest can be said once we have more findings. We should wait for the results," Dr VK Paul, a member of Niti Aayog, said.

The vaccine is being developed with support from the department of biotechnology (DBT) and Biotechnology Industry Research Associate Council (BIRAC).(File Photo / REUTERS)
The vaccine is being developed with support from the department of biotechnology (DBT) and Biotechnology Industry Research Associate Council (BIRAC).(File Photo / REUTERS)

After developing India’s first indigenous anti-Covid shot, Covaxin, the Hyderabad-based pharmaceutical company is now developing an intranasal jab for the country. It received regulatory approvals to conduct the second and third phase trials of the intranasal vaccine, BBV154, in August. Bharat Biotech's nasal vaccine clinical trial's principal investigator is Dr Sanjay Rai.

Unlock exclusive access to the latest news on India's general elections, only on the HT App. Download Now! Download Now!

The Phase 1 medial trial was conducted on health groups volunteers in the age group of 18-60. In a statement earlier, the ministry of science and technology said the vaccine was "well-tolerated" by the volunteers. The vaccine is being developed with support from the department of biotechnology (DBT) and Biotechnology Industry Research Associate Council (BIRAC).

According to Bharat Biotech's website, the nasal route for the vaccine has "excellent potential for vaccination due to the organised immune systems of the nasal mucosa." It will also be easier to administer and will not require trained health care workers. The nasal vaccine will also eliminate needle-associated risks such as injuries and infections. "It is ideally suited for children’s and adults," the company said.

Tell us what your First Vote will stand for in a short video & get a chance to be featured on HT’s social media handles. Click here to know more!

Get Current Updates on India News, Elections 2024, Lok Sabha Election 2024 Live, Election 2024 Date, Weather Today along with Latest News and Top Headlines from India and around the world.
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Thursday, May 23, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On